Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They presently have a $45.00 price target on the stock. Wedbush's target price would indicate a potential upside of 13.71% from the company's current price.

Several other research analysts have also commented on the company. Guggenheim lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 25th. Evercore ISI started coverage on shares of Spyre Therapeutics in a report on Tuesday, July 16th. They issued an "outperform" rating on the stock. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $46.43.

Spyre Therapeutics Price Performance

Shares of Spyre Therapeutics stock traded up $1.89 during trading hours on Friday, hitting $39.58. The company's stock had a trading volume of 428,878 shares, compared to its average volume of 507,507. The company has a market capitalization of $2.02 billion, a PE ratio of -2.56 and a beta of 2.90. The stock has a 50 day moving average of $30.54 and a 200 day moving average of $30.36. Spyre Therapeutics has a 12 month low of $8.43 and a 12 month high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.04. Equities analysts expect that Spyre Therapeutics will post -4.18 EPS for the current year.

Institutional Trading of Spyre Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Amalgamated Bank bought a new position in shares of Spyre Therapeutics during the second quarter valued at approximately $28,000. Quest Partners LLC acquired a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at about $36,000. SG Americas Securities LLC purchased a new position in Spyre Therapeutics in the 2nd quarter worth approximately $130,000. Carlyle Group Inc. purchased a new stake in shares of Spyre Therapeutics during the 2nd quarter valued at approximately $227,000. Finally, Profund Advisors LLC purchased a new stake in Spyre Therapeutics in the second quarter valued at approximately $296,000. Institutional investors own 80.39% of the company's stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.